The future of peptide medicine is about closing the gray market

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

As peptides surge in popularity, better evidence and cleaner supply chains could help the field grow without leaving patients behind.

Peptides have become one of longevity’s biggest concepts. However, behind the social media posts and “research use only” vials is a more complicated reality: demand is moving faster than the systems designed to make these compounds safe, understandable and accountable.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Kyle Umipig

Kyle has nine years of editorial writing experience. They have been following the longevity sector since 2022, focusing on research, emerging tech, and the companies shaping the future of aging and age-related health.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE